Inquiry Basket
CAS No.:
Cat No.: BADC-01349
4.5 
Azido-PEG4-Glu-Val-Cit-PAB-MMAE combines azide-functionalized PEG spacer with glutamic acid-modified valine-citrulline linker and MMAE payload, enabling bioorthogonal conjugation and precise release in ADC therapies. Keywords: azide linker, PEG spacer, MMAE payload, ADC drug delivery.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Azido-PEG4-Glu-Val-Cit-PAB-MMAE is a chemical conjugate used extensively in targeted cancer therapies. Here are some key applications of Azido-PEG4-Glu-Val-Cit-PAB-MMAE:
Antibody-Drug Conjugates (ADCs): Azido-PEG4-Glu-Val-Cit-PAB-MMAE is a critical linker-payload component in the development of ADCs. These conjugates consist of monoclonal antibodies specific to cancer cell antigens, linked to cytotoxic drugs via the Azido-PEG4-Glu-Val-Cit-PAB-MMAE linker. Upon binding to the cancer cell, the ADC is internalized and the cytotoxic drug is released, killing the cell while sparing healthy tissues.
Directed Drug Delivery: This conjugate is engineered for targeted drug delivery, enhancing the selective toxicity of chemotherapeutic agents. The PEGylation ensures increased solubility and stability, while the Val-Cit dipeptide ensures the payload is released specifically in the presence of tumor-specific proteases. This strategy minimizes systemic side effects and improves therapeutic efficacy.
Cell Imaging and Tracking: Azido-PEG4-Glu-Val-Cit-PAB-MMAE can be utilized in advanced cell imaging techniques. By tagging specific cells with this conjugate, researchers can track and image the distribution and proliferation of these cells in real-time. This application is critical for understanding tumor dynamics and the pharmacokinetics of therapeutic interventions.
Pharmacokinetic Studies: Researchers use Azido-PEG4-Glu-Val-Cit-PAB-MMAE in pharmacokinetic and biodistribution studies to assess the behavior of new drug candidates in the body. By conjugating drugs to this linker-payload, scientists can study how drugs are absorbed, distributed, metabolized, and excreted. These insights are vital for optimizing dosage regimens and improving drug safety profiles.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-00019 | Fmoc-VC-PAB-MMAE | 1350456-56-2 | |
| BADC-00849 | Acetylene-linker-Val-Cit-PABC-MMAE | 1411977-95-1 | |
| BADC-01448 | mDPR-Val-Cit-PAB-MMAE | 1491152-26-1 | |
| BADC-00958 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | |
| BADC-01348 | Val-Cit-PAB-MMAE TFA salt | 1608127-32-7 | |
| BADC-01435 | N-Ac-Cys-MC-VC-PAB-MMAE | 1628933-80-1 | |
| BADC-01408 | DBM(C6)-VC-PAB-MMAE | 1644228-55-6 | |
| BADC-01459 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 | |
| BADC-01638 | OH-Glu-Val-Cit-PAB-MMAE | 1895916-23-0 | |
| BADC-00855 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 |
Azido-PEG4-Glu-Val-Cit-PAB-MMAE
Required fields are marked with *
Azido-PEG4-Glu-Val-Cit-PAB-MMAE
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
